Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

Abstract

Sorafenib showed modest activity in ACC with a 12-month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation.